Compare ADMA & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADMA | PBH |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2012 | 2004 |
| Metric | ADMA | PBH |
|---|---|---|
| Price | $7.92 | $48.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $25.67 | ★ $75.33 |
| AVG Volume (30 Days) | ★ 6.0M | 758.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.19 | ★ 3.91 |
| Revenue | $42,219,783.00 | ★ $975,777,000.00 |
| Revenue This Year | $27.46 | N/A |
| Revenue Next Year | $22.11 | $4.31 |
| P/E Ratio | $43.03 | ★ $12.28 |
| Revenue Growth | ★ 43.85 | 36.77 |
| 52 Week Low | $7.21 | $42.62 |
| 52 Week High | $22.37 | $87.09 |
| Indicator | ADMA | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 30.12 | 34.90 |
| Support Level | $7.34 | $42.62 |
| Resistance Level | $16.02 | $62.91 |
| Average True Range (ATR) | 0.44 | 2.23 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 30.69 | 43.63 |
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.